News › GlobeNewswire Inc.

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

GlobeNewswire Inc. • Dec 22, 2025 8:00am (New York) •By Na

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Humacyte published long-term clinical data showing Symvess, a bioengineered vascular conduit, maintained structural integrity over 36 months with 92.9% infection-free rates, 82.5% limb salvage at 24 months, and no unprovoked structural failures in extremity arterial trauma patients. The results represent the first prospective long-term data for an off-the-shelf biologic conduit in traumatic arterial repair where autologous vein grafts are not feasible.

← Back to news Read Original Article

Insights

HUMA positive

Publication of positive long-term clinical data demonstrating safety, efficacy, and durability of Symvess with high limb salvage rates (82.5% at 24 months), low infection rates (92.9% infection-free), and no structural failures. FDA approval achieved in December 2024 for extremity vascular trauma indication, representing a significant commercial milestone for the company's lead product.

Keywords

#Symvess #acellular tissue engineered vessel #vascular trauma #limb salvage #bioengineered tissues #extremity arterial repair #clinical trial results #FDA approval

Tickers

HUMA HUMAW

← Prev: Abcourt annonce une entente avec Glencore AG portant sur un financement par dette senior et un contrat d’achat de production

Next: Stock Market Today: Dow Jones, S&P 500 Futures Climb At The Start Of Christmas Week— Kemper, Trump Media & Technology, cbdMD In Focus (UPDATED) →